menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna , Ph.D., one of Intellia Therapeutics , Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr.
Read More

Intellia Therapeutics Names John F. Crowley to Board of Directors

CAMBRIDGE, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed John F. Crowley to its Board of Directors. Mr.
Read More

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end
Read More

Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Chardan’s Virtual 4 th Annual Genetic Medicines
Read More

Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference

CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Baird’s 2020 Virtual Global Healthcare Conference on
Read More

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end Expanded Regeneron collaboration, receiving $100 million through upfront cash and equity investment and
Read More

Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its second quarter 2020 financial results and operational
Read More

Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. , June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , today announced the closing of an underwritten public offering of
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the pricing of an underwritten public offering of
Read More
RSS FEEDS
PRINT PAGE